Crassula Pharmaceuticals

About Crassula Pharmaceuticals

Crassula is a technology-driven pharmaceutical and life-sciences company specializing in advanced formulation development and GMP-compliant manufacturing. The company develops and produces solid, liquid, sterile, and topical dosage forms using validated process technologies and formulation science focused on improving stability, delivery performance, and bioavailability.

Certifications
  • Country/Region:
    United States
  • On CPHI since:
    2023
  • Certificates:
    2
  • Employees:
    500 - 999
Company types
Academic/Research
CMO/CDMO
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Nutraceuticals
Pharmaceutical Company (generic finished products)
Contact info

Products from Crassula Pharmaceuticals (3)

  • Q-Curviva™

    Product Q-Curviva™

    Q-Curviva™ is a high-performance curcumin raw material engineered using QuanticSphere™ (PQNS) phospholipid nano-delivery technology to overcome curcumin’s intrinsic limitations of poor solubility, rapid metabolism, and low oral bioavailability. The ingredient is designed for use in finished nutraceutical f...
  • Q-NiFlex™

    Product Q-NiFlex™

    Q-NiFlex™ is a next-generation 16-in-1 multi-target joint restoration nutraceutical engineered to support cartilage regeneration, joint protection, mobility, and long-term inflammation control. Formulated using QuanticSphere™ (PQNS) technology, Q-NiFlex™ overcomes the bioavailability limitations of convent...
  • Q-Vitalis™

    Product Q-Vitalis™

    Q-Vitalis™ is a next-generation magnesium raw material engineered with QuanticSphere™ (PQNS) phospholipid nano-delivery technology to overcome the low absorption and gastrointestinal limitations of conventional magnesium salts. The ingredient is designed to deliver magnesium efficiently at the cellular lev...

Crassula Pharmaceuticals Resources (2)

  • News Launch of QuanticSphere™ (PQNS) – Advanced Phospholipid Nano-Delivery Platform

    Crassula Pharmaceuticals announces the launch of QuanticSphere™ (PQNS), a proprietary phospholipid-based nano-delivery technology designed to improve the bioavailability, stability, and controlled release of nutraceutical and functional ingredients. The platform addresses absorption limitations commonly associated with lipophilic and poorly soluble actives and is available for ingredient and CDMO applications.
  • Video Q-NiFlex™ – Multi-Target Joint Support Formulation Powered by QuanticSphere™

    Q-NiFlex™ is a multi-ingredient joint support nutraceutical formulated using QuanticSphere™ (PQNS) phospholipid nano-delivery technology.

    The formulation integrates a broad matrix of structural, anti-inflammatory, antioxidant, and supportive actives designed to address key aspects of joint function, mobility, and long-term musculoskeletal support.

    QuanticSphere™ PQNS technology is applied to enhance the absorption, stability, and controlled release of traditionally low-bioavailability ingredients. This enables improved systemic exposure at lower doses while supporting gastrointestinal tolerance.

    Q-NiFlex™ is developed for nutraceutical and preventive health applications and is manufactured under WHO-GMP and ISO-certified quality systems, with scalability for global markets.